Zenith Capital (Zenith Capital) Marketable Securities : $0.00 Mil (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Zenith Capital's Marketable Securities for the quarter that ended in . 20 was $0.00 Mil.

Zenith Capital Marketable Securities Historical Data

The historical data trend for Zenith Capital's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Marketable Securities Chart

Zenith Capital Annual Data

Trend

Marketable Securities

Zenith Capital Quarterly Data

Marketable Securities

Zenith Capital Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Zenith Capital (OTCPK:ZHCLF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Zenith Capital Marketable Securities Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines